Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|June 10, 2015
How Greater Interest in Pharmacy Changed the Industry
Peter J. Rice, PharmD, PhD, BCPS, reflects on how the industry has changed as interest in pharmacy has grown.
Advertisement
Peter J. Rice, PharmD, PhD, BCPS, professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, reflects on how the industry has changed as interest in pharmacy has grown.
This video was recorded at APhA's Annual Meeting and Exposition in March 2015.
Advertisement
Related to this article
The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
CDC-recommended adult vaccination programs for pneumococcal disease, RSV, influenza, and COVID-19 prevent over 182,000 deaths and generate up to $12 in societal value for every $1 spent.
This article discusses a recent publication examining pharmacy access across Minnesota and explores the complex factors contributing to threatened community health access across the US.
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.
New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.
At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
3
Radioligand Therapy Doesn’t Need to Be Risk-Free—It Needs to Be Worth It
4
FDA Reduces Monitoring Time for First Two Tarlatamab Doses
5